Healthcare Executive Faints During Weight Loss Drug Announcement
Gordon Findlay, a healthcare executive from Novo Nordisk, fainted on Thursday at the Oval Office during an announcement about weight loss drugs.
Incident Details
During the event focused on GLP-1 drugs, the press conference was paused as President Donald Trump and Dr. Mehmet Oz turned their attention to Findlay. The press was quickly escorted out of the room while medical assistance was provided.
“During the Most Favored Nations Oval Office Announcement, a representative with one of the companies fainted,” said White House Press Secretary Karoline Leavitt. “The White House Medical Unit quickly jumped into action, and the gentleman is okay. The Press Conference will resume shortly.”
Announcement Context
At the event, President Trump announced a deal with Eli Lilly and Novo Nordisk to offer some obesity drugs at approximately $150 for a one-month supply. Multiple speakers addressed the audience, including Eli Lilly CEO David Ricks. It was during his speech that Findlay fainted.
Response and Recovery
- Press was quickly removed from the room following the incident.
- Dr. Kennedy left the room to get medical help for Findlay.
- The press conference resumed at 1:29 p.m., with Findlay expected to recover.
Summary: Novo Nordisk executive Gordon Findlay fainted during a White House announcement on affordable obesity drugs, but recovered quickly and the event continued.